⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18124809 | 1.00 | — | — | |
| SCHEMBL77211 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL18109763 | 0.97 | — | — | |
| SCHEMBL8678191 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL18109765 | 0.97 | — | — | |
| SCHEMBL174163 | 0.81 | — | — | |
| SCHEMBL17078042 | 0.78 | — | — | |
| SCHEMBL18874472 | 0.78 | — | — | |
| SCHEMBL3749311 | 0.78 | — | — | |
| SCHEMBL30978336 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737470-A2 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | Zikani Therapeutics , Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3883647-B1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-119462659-A | Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-113874079-B | Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240277747-A1 | Compounds for Treating Genetic Diseases | ZIKANI THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4358970-A1 | COMPOUNDS FOR TREATING GENETIC DISEASES | Zikani Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG | 2008-08-21 | — | — | US | disclosed |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG | 2008-08-21 | — | — | US | disclosed |
| WO-2008063912-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063912-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| EP-1912972-A1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | Novartis AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007021794-A1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021794-A1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | disclosed |